Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic evidence for serum amyloid P component as a drug target in neurodegenerative disorders.

Open biology - 1 Jul 2024

Schmidt A Floriaan, Finan Chris, Chopade Sandesh, Ellmerich Stephan, Rossor Martin N, Hingorani Aroon D, Pepys Mark B

Abstract excerpt

The mechanisms responsible for neuronal death causing cognitive loss in Alzheimer's disease (AD) and many other dementias are not known. Serum amyloid P component (SAP) is a constitutive plasma protein, which is cytotoxic for cerebral neurones and also promotes formation and persistence of cerebral Aβ amyloid and neurofibrillary tangles. Circulating SAP, which is produced exclusively by the liver, is normally...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Lewy Body Disease

Share to Mendelian Randomization Analysis

Share to Neurodegenerative Diseases

Share to Serum Amyloid P-Component

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 39013416
DOI: 10.1098/rsob.230419
PMCID: PMC11251762

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic evidence for serum amyloid P component as a drug target in neurodegenerative disorders.PMID 39013416Read ↗

Genetic evidence for serum amyloid P component as a drug target for treatment of neurodegenerative disordersSemantic proximity Read ↗

Identification of potential therapeutic targets for Alzheimer's disease from the proteomes of plasma and cerebrospinal fluid in a multicenter Mendelian randomization studySemantic proximity Read ↗

Pharmacogenomics and treatment for dementia induced by Alzheimer's disease.Semantic proximity Read ↗

Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.Semantic proximity Read ↗

A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly.Semantic proximity Read ↗

<i>APOE</i> genotype or presence of brain amyloid alters the plasma proteome in cognitively normal, elderly subjectsSemantic proximity Read ↗

APOE genotype and brain amyloid are associated with changes in the plasma proteome in elderly subjects without dementia.Semantic proximity Read ↗

Pharmacogenomics in Alzheimer's disease.Semantic proximity Read ↗

Amyloid, tau and risk of Alzheimer's disease: a Mendelian randomization study.Semantic proximity Read ↗

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assaySemantic proximity Read ↗

Blood-derived amyloid-β protein induces Alzheimer’s disease pathologiesSemantic proximity Read ↗

Pharmacogenomics and therapeutic strategies for dementiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.